Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response

References

• Kindt T, Goldsby RA, Osborne BA. Kuby Immunology (6th Edition). WH Freeman and Company, NY, USA (2007).
   Google Scholar
• Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med.340(6), 448–454 (1999).
   PubMed Web of Science ®Google Scholar
• Chrousos GP. The hypothalamic–pituitary–adrenal axis and immune-mediated inflammation. N. Engl. J. Med.332(20), 1351–1362 (1995).
   PubMed Web of Science ®Google Scholar
• Dienstag JL. Hepatitis B virus infection. N. Engl. J. Med.359(14), 1486–1500 (2008).
   PubMed Web of Science ®Google Scholar
• Schofield L, Grau GE. Immunological processes in malaria pathogenesis. Nat. Rev. Immunol.5(9), 722–735 (2005).
   PubMed Web of Science ®Google Scholar
• Naud J, Michaud J, Leblond FA, Lefrancois S, Bonnardeaux A, Pichette V. Effects of chronic renal failure on liver drug transporters. Drug Metab. Dispos.36(1), 124–128 (2007).
   PubMedGoogle Scholar
• O’Dell JR. Therapeutic strategies for rheumatoid arthritis. N. Engl. J. Med.350(25), 2591–2602 (2004).
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N. Engl. J. Med.361(5), 496–509 (2009).
   PubMed Web of Science ®Google Scholar
• Horwitz BJ, Fisher RS. The irritable bowel syndrome. N. Engl. J. Med.344(24), 1846–1850 (2001).
   PubMed Web of Science ®Google Scholar
• Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J. Clin. Invest.121(6), 2111–2117 (2011).
   PubMed Web of Science ®Google Scholar
• Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol.11(2), 98–107 (2011).
   PubMed Web of Science ®Google Scholar
• Slaviero KA, Clarke SJ, Rivory LP. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol.4(4), 224–232 (2003).
   PubMed Web of Science ®Google Scholar
• Ruot B, Bechereau F, Bayle G, Breuille D, Obled C. The response of liver albumin synthesis to infection in rats varies with the phase of the inflammatory process. Clin. Sci. (Lond.)102(1), 107–114 (2002).
   PubMedGoogle Scholar
• Moshage HJ, Janssen JA, Franssen JH, Hafkenscheid JC, Yap SH. Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation. J. Clin. Invest.79(6), 1635–1641 (1987).
   PubMed Web of Science ®Google Scholar
• Don BR, Kaysen G. Serum albumin: relationship to inflammation and nutrition. Semin. Dial.17(6), 432–437 (2004).
   PubMed Web of Science ®Google Scholar
• Morgan ET, Goralski KB, Piquette-Miller M et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab. Dispos.36(2), 205–216 (2008).
   PubMed Web of Science ®Google Scholar
• Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin. Pharmacol. Ther.85(4), 434–438 (2009).
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ et al. Membrane transporters in drug development. Nat. Rev. Drug Discov.9(3), 215–236 (2010).
   PubMed Web of Science ®Google Scholar
• Klaassen CD, Aleksunes LM. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacolog. Rev.62(1), 1–96 (2010).
   PubMed Web of Science ®Google Scholar
• Klaassen CD, Lu H. Xenobiotic transporters: ascribing function from gene knockout and mutation studies. Toxicol. Sci.101(2), 186–196 (2008).
   PubMed Web of Science ®Google Scholar
• Petrovic V, Teng S, Piquette-Miller M. Regulation of drug transporters during infection and inflammation. Mol. Intervent.7(2), 99–111 (2007).
   PubMed Web of Science ®Google Scholar
• Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl Cancer Inst.92(16), 1295–1302 (2000).
   PubMed Web of Science ®Google Scholar
• Higgins CF, Linton KJ. Structural biology. The xyz of ABC transporters. Science293(5536), 1782–1784 (2001).
   PubMed Web of Science ®Google Scholar
• Mannering GJ, Renton KW, El Azhary R, Deloria LB. Effects of interferon-inducing agents on hepatic cytochrome P-450 drug metabolizing systems. Ann. NY Acad. Sci.350, 314–331 (1980).
   PubMedGoogle Scholar
• Klein I, Sarkadi B, Varadi A. An inventory of the human ABC proteins. Biochim. Biophys. Acta1461(2), 237–262 (1999).
   PubMed Web of Science ®Google Scholar
• Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res.11(7), 1156–1166 (2001).
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, O’Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem.38(9), 1277–1287 (1990).
   PubMed Web of Science ®Google Scholar
• Richaud-Patin Y, Soto-Vega E, Jakez-Ocampo J, Llorente L. P-glycoprotein in autoimmune diseases. Autoimmun. Rev.3(3), 188–192 (2004).
   PubMed Web of Science ®Google Scholar
• Turriziani O, Gianotti N, Falasca F et al. Expression levels of MDR1, MRP1, MRP4, and MRP5 in peripheral blood mononuclear cells from HIV infected patients failing antiretroviral therapy. J. Med. Virol.80(5), 766–771 (2008).
   PubMed Web of Science ®Google Scholar
• Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug Deliv. Rev.27(2–3), 161–170 (1997).
   PubMed Web of Science ®Google Scholar
• Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica31(8–9), 469–497 (2001).
   PubMed Web of Science ®Google Scholar
• Tanigawara Y. Role of P-glycoprotein in drug disposition. Ther. Drug Monit.22(1), 137–140 (2000).
   PubMed Web of Science ®Google Scholar
• Slitt AL, Allen K, Morrone J et al. Regulation of transporter expression in mouse liver, kidney, and intestine during extrahepatic cholestasis. Biochim. Biophys. Acta1768(3), 637–647 (2007).
   PubMed Web of Science ®Google Scholar
• Keppler D. Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy. Handb. Exp. Pharmacol. (201), 299–323 (2011).
   PubMedGoogle Scholar
• Gao M, Loe DW, Grant CE, Cole SP, Deeley RG. Reconstitution of ATP-dependent leukotriene C4 transport by co-expression of both half-molecules of human multidrug resistance protein in insect cells. J. Biol. Chem.271(44), 27782–27787 (1996).
   PubMed Web of Science ®Google Scholar
• Eckford PD, Sharom FJ. ABC efflux pump-based resistance to chemotherapy drugs. Chem. Rev.109(7), 2989–3011 (2009).
   PubMed Web of Science ®Google Scholar
• Hinoshita E, Taguchi K, Inokuchi A et al. Decreased expression of an ATP-binding cassette transporter, MRP2, in human livers with hepatitis C virus infection. J. Hepatol.35(6), 765–773 (2001).
   PubMed Web of Science ®Google Scholar
• Borst P, Zelcer N, Van De Wetering K. MRP2 and 3 in health and disease. Cancer Lett.234(1), 51–61 (2006).
   PubMed Web of Science ®Google Scholar
• Ozvegy C, Litman T, Szakacs G et al. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem. Biophys. Res. Commun.285(1), 111–117 (2001).
   PubMed Web of Science ®Google Scholar
• Schwabedissen HE, Kroemer HK. In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2). Handb. Exp. Pharmacol. (201), 325–371 (2011).
   PubMedGoogle Scholar
• Maliepaard M, Van Gastelen MA, De Jong LA et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res.59(18), 4559–4563 (1999).
   PubMed Web of Science ®Google Scholar
• Maliepaard M, Scheffer GL, Faneyte IF et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res.61(8), 3458–3464 (2001).
   PubMed Web of Science ®Google Scholar
• Langmann T, Mauerer R, Zahn A et al. Real-time reverse transcription-PCR expression profiling of the complete human ATP-binding cassette transporter superfamily in various tissues. Clin. Chem.49(2), 230–238 (2003).
   PubMed Web of Science ®Google Scholar
• Burger H, Nooter K. Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib. Cell Cycle3(12), 1502–1505 (2004).
   PubMed Web of Science ®Google Scholar
• Englund G, Rorsman F, Rönnblom A et al. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur. J. Pharm. Sci.29(3–4), 269–277 (2006).
   PubMed Web of Science ®Google Scholar
• Elferink RPJO, Groen AK. Mechanisms of biliary lipid secretion and their role in lipid homeostasis. Semin. Liver Dis.20(3), 293–305 (2000).
   PubMedGoogle Scholar
• Fickert P, Fuchsbichler A, Wagner M et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology127(1), 261–274 (2004).
   PubMed Web of Science ®Google Scholar
• Mauad TH, Van Nieuwkerk CM, Dingemans KP et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am. J. Pathol.145(5), 1237–1245 (1994).
   PubMed Web of Science ®Google Scholar
• Stapelbroek JM, Van Erpecum KJ, Klomp LW, Houwen RH. Liver disease associated with canalicular transport defects: current and future therapies. J. Hepatol.52(2), 258–271 (2010).
   PubMed Web of Science ®Google Scholar
• Hediger MA, Romero MF, Peng JB, Rolfs A, Takanaga H, Bruford EA. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins. Pflgers Arch. Eur. J. Physiol.447(5), 465–468 (2004).
   PubMed Web of Science ®Google Scholar
• Konig J. Uptake transporters of the human OATP family: molecular characteristics, substrates, their role in drug–drug interactions, and functional consequences of polymorphisms. Handb. Exp. Pharmacol.201, 1–28 (2011).
   PubMedGoogle Scholar
• Fahrmayr C, Fromm MF, Konig J. Hepatic OATP and OCT uptake transporters: their role for drug–drug interactions and pharmacogenetic aspects. Drug Metab. Rev.42(3), 380–401 (2010).
   PubMed Web of Science ®Google Scholar
• Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br. J. Pharmacol.158(3), 693–705 (2009).
   PubMed Web of Science ®Google Scholar
• Burckhardt G, Burckhardt BC. In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy. Handb. Exp. Pharmacol. (201), 29–104 (2011).
   PubMedGoogle Scholar
• Hagenbuch B, Gui C. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica38(7–8), 778–801 (2008).
   PubMed Web of Science ®Google Scholar
• Svoboda M, Riha J, Wlcek K, Jaeger W, Thalhammer T. Organic anion transporting polypeptides (OATPs): regulation of expression and function. Curr. Drug Metab.12(2), 139–153 (2011).
   PubMed Web of Science ®Google Scholar
• Leuthold S, Hagenbuch B, Mohebbi N, Wagner CA, Meier PJ, Stieger B. Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters. Am. J. Physiol. Cell Physiol.296(3), C570–C582 (2009).
   PubMed Web of Science ®Google Scholar
• Wright SH. Role of organic cation transporters in the renal handling of therapeutic agents and xenobiotics. Toxicol. Appl. Pharmacol.204(3), 309–319 (2005).
   PubMed Web of Science ®Google Scholar
• Ciarimboli G. Organic cation transporters. Xenobiotica38(7–8), 936–971 (2008).
   PubMed Web of Science ®Google Scholar
• Nigam SK, Bush KT, Bhatnagar V. Drug and toxicant handling by the OAT organic anion transporters in the kidney and other tissues. Nat. Clin. Pract. Nephrol.3(8), 443–448 (2007).
   PubMedGoogle Scholar
• Rizwan AN, Burckhardt G. Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm. Res.24(3), 450–470 (2007).
   PubMed Web of Science ®Google Scholar
• Nies AT, Koepsell H, Damme K, Schwab M. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb. Exp. Pharmacol. (201), 105–167 (2011).
   PubMedGoogle Scholar
• Ciarimboli G. Role of organic cation transporters in drug-induced toxicity. Exp. Opin. Drug Metab. Toxicol.7(2), 159–174 (2011).
   PubMed Web of Science ®Google Scholar
• Fortier ME, Kent S, Ashdown H, Poole S, Boksa P, Luheshi GN. The viral mimic, polyinosinic:polycytidylic acid, induces fever in rats via an interleukin-1-dependent mechanism. Am. J. Physiol. Regul. Integr. Comp. Physiol.287(4), R759–R766 (2004).
   Web of Science ®Google Scholar
• Siewert E, Bort R, Kluge R, Heinrich PC, Castell J, Jover R. Hepatic cytochrome P450 down-regulation during aseptic inflammation in the mouse is interleukin 6 dependent. Hepatology32(1), 49–55 (2000).
   PubMed Web of Science ®Google Scholar
• Renton KW. Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol. Ther.92(2–3), 147–163 (2001).
   PubMed Web of Science ®Google Scholar
• Shedlofsky SI, Israel BC, Tosheva R, Blouin RA. Endotoxin depresses hepatic cytochrome P450-mediated drug metabolism in women. Br. J. Clin. Pharmacol.43(6), 627–632 (1997).
   PubMed Web of Science ®Google Scholar
• Shedlofsky SI, Israel BC, Mcclain CJ, Hill DB, Blouin RA. Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J. Clin. Invest.94(6), 2209–2214 (1994).
   PubMed Web of Science ®Google Scholar
• Poloyac SM, Tosheva RT, Gardner BM, Shedlofsky SI, Blouin RA. The effect of endotoxin administration on the pharmacokinetics of chlorzoxazone in humans. Clin. Pharmacol. Ther.66(6), 554–562 (1999).
   PubMed Web of Science ®Google Scholar
• Roe AL, Warren G, Hou G, Howard G, Shedlofsky SI, Blouin RA. The effect of high dose endotoxin on CYP3A2 expression in the rat. Pharm. Res.15(10), 1603–1608 (1998).
   PubMedGoogle Scholar
• Piquette-Miller M, Pak A, Kim H, Anari R, Shahzamani A. Decreased expression and activity of P-glycoprotein in rat liver during acute inflammation. Pharm. Res.15(5), 706–711 (1998).
   PubMed Web of Science ®Google Scholar
• Sukhai M, Yong A, Kalitsky J, Piquette-Miller M. Inflammation and interleukin-6 mediate reductions in the hepatic expression and transcription of the Mdr1a and Mdr1b genes. Mol. Cell Biol. Res. Commun.4(4), 248–256 (2000).
   PubMedGoogle Scholar
• Cherrington NJ, Slitt AL, Li N, Klaassen CD. Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats. Drug Metab. Dispos.32(7), 734–741 (2004).
   PubMed Web of Science ®Google Scholar
• Hartmann G, Kim H, Piquette-Miller M. Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines in mice. Int. Immunopharmacol.1(2), 189–199 (2001).
   PubMed Web of Science ®Google Scholar
• Vos TA, Hooiveld GJ, Koning H et al. Up-regulation of the multidrug resistance genes, Mrp1 and Mdr1b, and down-regulation of the organic anion transporter, Mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver. Hepatology28(6), 1637–1644 (1998).
   PubMed Web of Science ®Google Scholar
• Goralski KB, Hartmann G, Piquette-Miller M, Renton KW. Downregulation of Mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin. Br. J. Pharmacol.139(1), 35–48 (2003).
   PubMed Web of Science ®Google Scholar
• Hartmann G, Vassileva V, Piquette-Miller M. Impact of endotoxin-induced changes in P-glycoprotein expression on disposition of doxorubicin in mice. Drug Metab. Dispos.33(6), 820–828 (2005).
   PubMed Web of Science ®Google Scholar
• Wang JH, Scollard DA, Teng S, Reilly RM, Piquette-Miller M. Detection of P-glycoprotein activity in endotoxemic rats by 99mTc-sestamibi imaging. J. Nucl. Med.46(9), 1537–1545 (2005).
   PubMed Web of Science ®Google Scholar
• Hidemura K, Zhao YL, Ito K et al. Shiga-like toxin II impairs hepatobiliary transport of doxorubicin in rats by down-regulation of hepatic P glycoprotein and multidrug resistance-associated protein Mrp2. Antimicrob. Agents Chemother.47(5), 1636–1642 (2003).
   PubMed Web of Science ®Google Scholar
• Lee G, Piquette-Miller M. Influence of IL-6 on MDR and MRP-mediated multidrug resistance in human hepatoma cells. Can. J. Physiol. Pharmacol.79(10), 876–884 (2001).
   PubMed Web of Science ®Google Scholar
• Miyoshi M, Nadai M, Nitta A et al. Role of tumor necrosis factor-α in down-regulation of hepatic cytochrome P450 and P-glycoprotein by endotoxin. Eur. J. Pharmacol.507(1–3), 229–237 (2005).
   PubMedGoogle Scholar
• Kalitsky-Szirtes J, Shayeganpour A, Brocks DR, Piquette-Miller M. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats. Drug Metab. Dispos.32(1), 20–27 (2004).
   PubMed Web of Science ®Google Scholar
• Blokzijl H, Vander Borght S, Bok LI et al. Decreased P-glycoprotein (P-gp/MDR1) expression in inflamed human intestinal epithelium is independent of PXR protein levels. Inflamm. Bowel Dis.13(6), 710–720 (2007).
   PubMed Web of Science ®Google Scholar
• Belliard AM, Lacour B, Farinotti R, Leroy C. Effect of tumor necrosis factor-α and interferon-γ on intestinal P-glycoprotein expression, activity, and localization in Caco-2 cells. J. Pharmaceut. Sci.93(6), 1524–1536 (2004).
   PubMed Web of Science ®Google Scholar
• Buyse M, Radeva G, Bado A, Farinotti R. Intestinal inflammation induces adaptation of P-glycoprotein expression and activity. Biochem. Pharmacol.69(12), 1745–1754 (2005).
   PubMed Web of Science ®Google Scholar
• Zhao YL, Du J, Kanazawa H et al. Effect of endotoxin on doxorubicin transport across blood–brain barrier and P-glycoprotein function in mice. Eur. J. Pharmacol.445(1–2), 115–123 (2002).
   PubMed Web of Science ®Google Scholar
• Ronaldson PT, Bendayan R. HIV-1 viral envelope glycoprotein gp120 triggers an inflammatory response in cultured rat astrocytes and regulates the functional expression of P-glycoprotein. Mol. Pharmacol.70(3), 1087–1098 (2006).
   PubMed Web of Science ®Google Scholar
• Poller B, Drewe J, Krahenbuhl S, Huwyler J, Gutmann H. Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood–brain barrier. Cell Mol. Neurobiol.30(1), 63–70 (2010).
   PubMed Web of Science ®Google Scholar
• Ando H, Nishio Y, Ito K et al. Effect of endotoxin on P-glycoprotein-mediated biliary and renal excretion of rhodamine-123 in rats. Antimicrob. Agents Chemother.45(12), 3462–3467 (2001).
   PubMedGoogle Scholar
• Heemskerk S, Van Koppen A, Van Den Broek L et al. Nitric oxide differentially regulates renal ATP-binding cassette transporters during endotoxemia. Pflugers Arch.454(2), 321–334 (2007).
   PubMedGoogle Scholar
• Evseenko DA, Paxton JW, Keelan JA. Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors. Drug Metab. Dispos.35(4), 595–601 (2007).
   PubMed Web of Science ®Google Scholar
• Chen YH, Wang JP, Wang H et al. Lipopolysaccharide treatment downregulates the expression of the pregnane X receptor, cyp3a11 and Mdr1a genes in mouse placenta. Toxicology211(3), 242–252 (2005).
   PubMed Web of Science ®Google Scholar
• Petrovic V, Wang JH, Piquette-Miller M. Effect of endotoxin on the expression of placental drug transporters and glyburide disposition in pregnant rats. Drug Metab. Dispos.36(9), 1944–1950 (2008).
   PubMed Web of Science ®Google Scholar
• Petrovic V, Piquette-Miller M. Impact of polyinosinic/polycytidylic acid on placental and hepatobiliary drug transporters in pregnant rats. Drug Metab. Dispos.38(10), 1760–1766 (2010).
   PubMed Web of Science ®Google Scholar
• Mason CW, Buhimschi IA, Buhimschi CS, Dong Y, Weiner CP, Swaan PW. ATP-binding cassette transporter expression in human placenta as a function of pregnancy condition. Drug Metab. Dispos.39(6), 1000–1007 (2011).
   PubMed Web of Science ®Google Scholar
• Vee ML, Lecureur V, Stieger B, Fardel O. Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-α or interleukin-6. Drug Metab. Dispos.37(3), 685–693 (2009).
   PubMed Web of Science ®Google Scholar
• Le Vee M, Jouan E, Moreau A, Fardel O. Regulation of drug transporter mRNA expression by interferon-γ in primary human hepatocytes. Fundam. Clin. Pharmacol.25(1), 99–103 (2011).
   PubMed Web of Science ®Google Scholar
• Von Wedel-Parlow M, Wolte P, Galla HJ. Regulation of major efflux transporters under inflammatory conditions at the blood–brain barrier in vitro. J. Neurochem.111(1), 111–118 (2009).
   PubMed Web of Science ®Google Scholar
• Hartmann G, Cheung AK, Piquette-Miller M. Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J. Pharmacol. Exp. Ther.303(1), 273–281 (2002).
   PubMed Web of Science ®Google Scholar
• Nakamura J, Nishida T, Hayashi K et al. Kupffer cell-mediated down regulation of rat hepatic CMOAT/MRP2 gene expression. Biochem. Biophys. Res. Commun.255(1), 143–149 (1999).
   PubMed Web of Science ®Google Scholar
• Tang W, Yi C, Kalitsky J, Piquette-Miller M. Endotoxin downregulates hepatic expression of P-glycoprotein and MRP2 in 2-acetylaminofluorene-treated rats. Mol. Cell Biol. Res. Commun.4(2), 90–97 (2000).
   PubMedGoogle Scholar
• Diao L, Li N, Brayman TG, Hotz KJ, Lai Y. Regulation of MRP2/ABCC2 and BSEP/ABCB11 expression in sandwich cultured human and rat hepatocytes exposed to inflammatory cytokines TNF-α, IL-6, and IL-1β. J. Biol. Chem.285(41), 31185–31192 (2010).
   PubMed Web of Science ®Google Scholar
• Le Vee M, Gripon P, Stieger B, Fardel O. Down-regulation of organic anion transporter expression in human hepatocytes exposed to the proinflammatory cytokine interleukin 1β. Drug Metab. Dispos.36(2), 217–222 (2008).
   PubMed Web of Science ®Google Scholar
• Donner MG, Keppler D. Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver. Hepatology34(2), 351–359 (2001).
   PubMed Web of Science ®Google Scholar
• Fardel O, Le Vee M. Regulation of human hepatic drug transporter expression by pro-inflammatory cytokines. Exp. Opin. Drug Metabol. Toxicol.5(12), 1469–1481 (2009).
   PubMed Web of Science ®Google Scholar
• Siewert E, Dietrich CG, Lammert F et al. Interleukin-6 regulates hepatic transporters during acute-phase response. Biochem. Biophys. Res. Commun.322(1), 232–238 (2004).
   PubMed Web of Science ®Google Scholar
• Jaisue S, Gerber JP, Davey AK. Pharmacokinetics of fexofenadine following LPS administration to rats. Xenobiotica40(11), 743–750 (2010).
   PubMed Web of Science ®Google Scholar
• Yang H, Plosch T, Lisman T et al. Inflammation mediated down-regulation of hepatobiliary transporters contributes to intrahepatic cholestasis and liver damage in murine biliary atresia. Pediatr. Res.66(4), 380–385 (2009).
   PubMedGoogle Scholar
• Lawrence RC, Felson DT, Helmick CG et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum.58(1), 26–35 (2008).
   PubMed Web of Science ®Google Scholar
• Helmick CG, Felson DT, Lawrence RC et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum.58(1), 15–25 (2008).
   PubMed Web of Science ®Google Scholar
• Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med.344(12), 907–916 (2001).
   PubMed Web of Science ®Google Scholar
• Symmons DP, Gabriel SE. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat. Rev. Rheumatol.7(7), 399–408 (2011).
   PubMed Web of Science ®Google Scholar
• Van Der Heijden JW, Dijkmans BA, Scheper RJ, Jansen G. Drug insight: resistance to methotrexate and other disease-modifying antirheumatic drugs – from bench to bedside. Nat. Clin. Pract. Rheumatol.3(1), 26–34 (2007).
   PubMedGoogle Scholar
• Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl Acad. Sci. USA89(20), 9784–9788 (1992).
   PubMed Web of Science ®Google Scholar
• Hung DY, Siebert GA, Chang P et al. Hepatic pharmacokinetics of propranolol in rats with adjuvant-induced systemic inflammation. Am. J. Physiol. Gastrointest. Liver Physiol.290(2), G343–G351 (2006).
   PubMed Web of Science ®Google Scholar
• Wang Y, Fang Y, Huang W et al. Effect of sinomenine on cytokine expression of macrophages and synoviocytes in adjuvant arthritis rats. J. Ethnopharmacol.98(1–2), 37–43 (2005).
   PubMed Web of Science ®Google Scholar
• Shibata NSH, Minouchi T, Yamaji A. Pharmacokinetics of cyclosporin A after intravenous administration to rats in various disease states. Biol. Pharm. Bull.16(11), 1130–1135 (1993).
   PubMed Web of Science ®Google Scholar
• Piquette-Miller M, Jamali F. Effect of adjuvant arthritis on the disposition of acebutolol enantiomer in rats. Agents Actions37, 290–296 (1992).
   PubMedGoogle Scholar
• Piquette-Miller M, Jamali F. Selective effect of adjuvant arthritis on the disposition of propranolol enantiomers in rats detected using a stereospecific HPLC assay. Pharm. Res.10(2), 294–299 (1993).
   PubMed Web of Science ®Google Scholar
• Dipasquale G, Welaj P, Rassaert CL. Prolonged pentobarbital sleeping time in adjuvant-induced polyarthritic rats. Res. Commun. Chem. Pathol. Pharmacol.9(2), 253–264 (1974).
   PubMedGoogle Scholar
• Sanada H, Sekimoto M, Kamoshita A, Degawa M. Changes in expression of hepatic cytochrome P450 subfamily enzymes during development of adjuvant-induced arthritis in rats. J. Toxicol. Sci.36(2), 181–190 (2011).
   PubMedGoogle Scholar
• Ling S. Effect of early phase adjuvant arthritis on hepatic p450 enzymes and pharmacokinetics of verapamil: an alternative approach to the use of an animal model of inflammation for pharmacokinetic studies. Drug Metab. Dispos.33(4), 579–586 (2005).
   PubMedGoogle Scholar
• Whitehouse MW, Beck FJ. Impaired drug metabolism in rats with adjuvant-induced arthritis: a brief review. Drug Metab. Dispos.1(1), 251–255 (1973).
   PubMed Web of Science ®Google Scholar
• Ferrari L, Jouzeau JY, Gillet P et al. Interleukin-1 β differentially represses drug-metabolizing enzymes in arthritic female rats. J. Pharmacol. Exp. Ther.264(2), 1012–1020 (1993).
   PubMed Web of Science ®Google Scholar
• Meunier CJ, Verbeeck RK. Glucuronidation of R- and S-ketoprofen, acetaminophen, and diflunisal by liver microsomes of adjuvant-induced arthritic rats. Drug Metab. Dispos.27(1), 26–31 (1999).
   PubMed Web of Science ®Google Scholar
• Achira M, Totsuka R, Fujimura H, Kume T. Tissue-specific regulation of expression and activity of P-glycoprotein in adjuvant arthritis rats. Eur. J. Pharm. Sci.16(1–2), 29–36 (2002).
   PubMedGoogle Scholar
• Uno S, Uraki M, Ito A et al. Changes in mRNA expression of ABC and SLC transporters in liver and intestines of the adjuvant-induced arthritis rat. Biopharm. Drug Dispos.30(1), 49–54 (2009).
   PubMed Web of Science ®Google Scholar
• Uno S, Kawase A, Tsuji A, Tanino T, Iwaki M. Decreased intestinal CYP3A and P-glycoprotein activities in rats with adjuvant arthritis. Drug Metab. Pharmacokinet.22(4), 313–321 (2007).
   PubMed Web of Science ®Google Scholar
• Anthony DD, Haqqi TM. Collagen-induced arthritis in mice: an animal model to study the pathogenesis of rheumatoid arthritis. Clin. Exp. Rheumatol.17(2), 240–244 (1999).
   PubMed Web of Science ®Google Scholar
• Kawase A, Tsunokuni Y, Iwaki M. Effects of alterations in CAR on bilirubin detoxification in mouse collagen-induced arthritis. Drug Metab. Dispos.35(2), 256–261 (2006).
   PubMedGoogle Scholar
• Kawase A, Yoshida I, Tsunokuni Y, Iwaki M. Decreased PXR and CAR inhibit transporter and CYP mRNA levels in the liver and intestine of mice with collagen-induced arthritis. Xenobiotica37(4), 366–374 (2007).
   PubMed Web of Science ®Google Scholar
• Mayo PR, Skeith K, Russell AS, Jamali F. Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis. Br. J. Clin. Pharmacol.50(6), 605–613 (2000).
   PubMed Web of Science ®Google Scholar
• Schmith VD, Foss JF. Inflammation: planning for a source of pharmacokinetic/pharmacodynamic variability in translational studies. Clin. Pharmacol. Ther.87(4), 488–491 (2010).
   PubMedGoogle Scholar
• Abraham C, Cho JH. Inflammatory bowel disease. N. Engl. J. Med.361(21), 2066–2078 (2009).
   PubMed Web of Science ®Google Scholar
• Loftus EV Jr, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterol. Clin. N. Am.31(1), 1–20 (2002).
   PubMed Web of Science ®Google Scholar
• Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol.3(7), 521–533 (2003).
   PubMed Web of Science ®Google Scholar
• Yan Y, Kolachala V, Dalmasso G et al. Temporal and spatial analysis of clinical and molecular parameters in dextran sodium sulfate induced colitis. PLoS One4(6), e6073 (2009).
   PubMed Web of Science ®Google Scholar
• Raddatz D, Bockemuhl M, Ramadori G. Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome. Eur. J. Gastroenterol. Hepatol.17(5), 547–557 (2005).
   PubMedGoogle Scholar
• Choung RS, Locke GR 3rd. Epidemiology of IBS. Gastroenterol. Clin. N. Am.40(1), 1–10 (2011).
   PubMed Web of Science ®Google Scholar
• Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology140(6), 1785.e4–1794.e4 (2011).
   Google Scholar
• Turner JR. Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. Am. J. Pathol.169(6), 1901–1909 (2006).
   PubMed Web of Science ®Google Scholar
• Dietrich CG, Geier A, Oude Elferink RP. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut52(12), 1788–1795 (2003).
   PubMed Web of Science ®Google Scholar
• Maclean C, Moenning U, Reichel A, Fricker G. Closing the gaps: a full scan of the intestinal expression of p-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats. Drug Metab. Dispos.36(7), 1249–1254 (2008).
   PubMed Web of Science ®Google Scholar
• Stephens RH, Tanianis-Hughes J, Higgs NB, Humphrey M, Warhurst G. Region-dependent modulation of intestinal permeability by drug efflux transporters: in vitro studies in Mdr1a(-/-) mouse intestine. J. Pharmacol. Exp. Ther.303(3), 1095–1101 (2002).
   PubMed Web of Science ®Google Scholar
• Van Herwaarden AE, Jonker JW, Wagenaar E et al. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res.63(19), 6447–6452 (2003).
   PubMed Web of Science ®Google Scholar
• Schneider RE, Babb J, Bishop H, Mitchard M, Hoare AM. Plasma levels of propranolol in treated patients with coeliac disease and patients with Crohn’s disease. Br. Med. J.2(6039), 794–795 (1976).
   PubMed Web of Science ®Google Scholar
• Langmann T, Moehle C, Mauerer R et al. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology127(1), 26–40 (2004).
   PubMed Web of Science ®Google Scholar
• Iizasa H, Genda N, Kitano T et al. Altered expression and function of P-glycoprotein in dextran sodium sulfate-induced colitis in mice. J. Pharm. Sci.92(3), 569–576 (2003).
   PubMed Web of Science ®Google Scholar
• Suzuki R, Miyamoto S, Yasui Y, Sugie S, Tanaka T. Global gene expression analysis of the mouse colonic mucosa treated with azoxymethane and dextran sodium sulfate. BMC Cancer7, 84 (2007).
   PubMed Web of Science ®Google Scholar
• Buyse M, Radeva G, Bado A, Farinotti R. Intestinal inflammation induces adaptation of P-glycoprotein expression and activity. Biochem. Pharmacol.69(12), 1745–1754 (2005).
   PubMed Web of Science ®Google Scholar
• Jahnel J, Fickert P, Langner C et al. Impact of experimental colitis on hepatobiliary transporter expression and bile duct injury in mice. Liver Int.29(9), 1316–1325 (2009).
   PubMed Web of Science ®Google Scholar
• Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, Mdr1a, spontaneously develop colitis. J. Immunol.161(10), 5733–5744 (1998).
   PubMed Web of Science ®Google Scholar
• Englund G, Jacobson A, Rorsman F, Artursson P, Kindmark A, Rönnblom A. Efflux transporters in ulcerative colitis: decreased expression of BCRP (ABCG2) and Pgp (ABCB1). Inflamm. Bowel Dis.13(3), 291–297 (2007).
   PubMed Web of Science ®Google Scholar
• Blokzijl H, Van Steenpaal A, Vander Borght S et al. Up-regulation and cytoprotective role of epithelial multidrug resistance-associated protein 1 in inflammatory bowel disease. J. Biol. Chem.283(51), 35630–35637 (2008).
   PubMed Web of Science ®Google Scholar
• Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science220(4597), 568–575 (1983).
   PubMed Web of Science ®Google Scholar
• Loe DW, Almquist KC, Deeley RG, Cole SP. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J. Biol. Chem.271(16), 9675–9682 (1996).
   PubMed Web of Science ®Google Scholar
• Wojtal KA, Eloranta JJ, Hruz P et al. Changes in mRNA expression levels of solute carrier transporters in inflammatory bowel disease patients. Drug Metab. Dispos.37(9), 1871–1877 (2009).
   PubMedGoogle Scholar
• Naud J, Michaud J, Beauchemin S et al. Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats. Drug Metab. Dispos.39(8), 1363–1369 (2011).
   PubMed Web of Science ®Google Scholar
• Michaud J, Nolin TD, Naud J et al. Effect of hemodialysis on hepatic cytochrome P450 functional expression. J. Pharmacol. Sci.108(2), 157–163 (2008).
   PubMed Web of Science ®Google Scholar
• Michaud J, Dube P, Naud J et al. Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br. J. Pharmacol.144(8), 1067–1077 (2005).
   PubMed Web of Science ®Google Scholar
• Villeneuve JP, Pichette V. Cytochrome P450 and liver diseases. Curr. Drug Metab.5(3), 273–282 (2004).
   PubMed Web of Science ®Google Scholar
• Guevin C, Michaud J, Naud J, Leblond FA, Pichette V. Down-regulation of hepatic cytochrome p450 in chronic renal failure: role of uremic mediators. Br. J. Pharmacol.137(7), 1039–1046 (2002).
   PubMed Web of Science ®Google Scholar
• Leblond FA, Petrucci M, Dube P, Bernier G, Bonnardeaux A, Pichette V. Downregulation of intestinal cytochrome p450 in chronic renal failure. J. Am. Soc. Nephrol.13(6), 1579–1585 (2002).
   PubMed Web of Science ®Google Scholar
• Leblond F, Guevin C, Demers C, Pellerin I, Gascon-Barre M, Pichette V. Downregulation of hepatic cytochrome P450 in chronic renal failure. J. Am. Soc. Nephrol.12(2), 326–332 (2001).
   PubMed Web of Science ®Google Scholar
• Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol. Ther.109(1–2), 1–11 (2006).
   PubMed Web of Science ®Google Scholar
• Nolin TD, Frye RF, Matzke GR. Hepatic drug metabolism and transport in patients with kidney disease. Am. J. Kidney Dis.42(5), 906–925 (2003).
   PubMed Web of Science ®Google Scholar
• Nolin TD, Naud J, Leblond FA, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin. Pharmacol. Ther.83(6), 898–903 (2008).
   PubMed Web of Science ®Google Scholar
• Naud J, Michaud J, Leblond FA, Lefrancois S, Bonnardeaux A, Pichette V. Effects of chronic renal failure on liver drug transporters. Drug Metab. Dispos.36(1), 124–128 (2008).
   PubMed Web of Science ®Google Scholar
• Vanholder R, De Smet R, Glorieux G et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int.63(5), 1934–1943 (2003).
   PubMed Web of Science ®Google Scholar
• Mak RH, Cheung W, Cone RD, Marks DL. Mechanisms of disease: cytokine and adipokine signaling in uremic cachexia. Nat. Clin. Pract. Nephrol.2(9), 527–534 (2006).
   PubMedGoogle Scholar
• Naud J, Michaud J, Boisvert C et al. Down-regulation of intestinal drug transporters in chronic renal failure in rats. J. Pharmacol. Exp. Ther.320(3), 978–985 (2007).
   PubMed Web of Science ®Google Scholar
• Ji L, Masuda S, Saito H, Inui K. Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy. Kidney Int.62(2), 514–524 (2002).
   PubMed Web of Science ®Google Scholar
• Laouari D, Yang R, Veau C, Blanke I, Friedlander G. Two apical multidrug transporters, P-gp and MRP2, are differently altered in chronic renal failure. Am. J. Physiol. Renal Physiol.280(4), F636–F645 (2001).
   PubMed Web of Science ®Google Scholar
• Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. Nat. Rev. Immunol.11(2), 131–142 (2011).
   PubMed Web of Science ®Google Scholar
• Morohoshi M, Fujisawa K, Uchimura I, Numano F. The effect of glucose and advanced glycosylation end products on IL-6 production by human monocytes. Ann. NY Acad. Sci.748, 562–570 (1995).
   PubMed Web of Science ®Google Scholar
• Morohoshi M, Fujisawa K, Uchimura I, Numano F. Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes45(7), 954–959 (1996).
   PubMed Web of Science ®Google Scholar
• Esposito K, Nappo F, Marfella R et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation106(16), 2067–2072 (2002).
   PubMed Web of Science ®Google Scholar
• Weisberg SP, Mccann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest.112(12), 1796–1808 (2003).
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science259(5091), 87–91 (1993).
   PubMed Web of Science ®Google Scholar
• Xu H, Barnes GT, Yang Q et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest.112(12), 1821–1830 (2003).
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing Type 2 diabetes mellitus. JAMA286(3), 327–334 (2001).
   PubMed Web of Science ®Google Scholar
• Spranger J, Kroke A, Mohlig M et al. Inflammatory cytokines and the risk to develop Type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study. Diabetes52(3), 812–817 (2003).
   PubMed Web of Science ®Google Scholar
• Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia40(11), 1286–1292 (1997).
   PubMed Web of Science ®Google Scholar
• Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol.11(2), 136–140 (2010).
   PubMed Web of Science ®Google Scholar
• Maedler K, Sergeev P, Ris F et al. Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest.110(6), 851–860 (2002).
   PubMed Web of Science ®Google Scholar
• Ehses JA, Perren A, Eppler E et al. Increased number of islet-associated macrophages in Type 2 diabetes. Diabetes56(9), 2356–2370 (2007).
   PubMed Web of Science ®Google Scholar
• Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin. Pharmacokinet.49(2), 71–87 (2010).
   PubMed Web of Science ®Google Scholar
• Lee JH, Yang SH, Oh JM, Lee MG. Pharmacokinetics of drugs in rats with diabetes mellitus induced by alloxan or streptozocin: comparison with those in patients with Type I diabetes mellitus. J. Pharm. Pharmacol.62(1), 1–23 (2010).
   PubMed Web of Science ®Google Scholar
• Yu S, Yu Y, Liu L et al. Increased plasma exposures of five protoberberine alkaloids from coptidis rhizoma in streptozotocin-induced diabetic rats: is P-GP involved? Planta Medica76(09), 876–881 (2010).
   PubMed Web of Science ®Google Scholar
• Hasegawa Y, Kishimoto S, Shibatani N et al. The pharmacokinetics of morphine and its glucuronide conjugate in a rat model of streptozotocin-induced diabetes and the expression of MRP2, MRP3 and UGT2B1 in the liver. J. Pharm. Pharmacol.62(3), 310–314 (2010).
   PubMed Web of Science ®Google Scholar
• Hasegawa Y, Kishimoto S, Shibatani N, Inotsume N, Takeuchi Y, Fukushima S. The disposition of pravastatin in a rat model of streptozotocin-induced diabetes and organic anion transporting polypeptide 2 and multidrug resistance-associated protein 2 expression in the liver. Biol. Pharm. Bull.33(1), 153–156 (2010).
   PubMed Web of Science ®Google Scholar
• Anger GJ, Magomedova L, Piquette-Miller M. Impact of acute streptozotocin-induced diabetes on ABC transporter expression in rats. Chem. Biodivers.6(11), 1943–1959 (2009).
   PubMedGoogle Scholar
• Liu Y, Liu H, Yang J et al. Increased amyloid β-peptide (1-40) level in brain of streptozotocin-induced diabetic rats. Neuroscience153(3), 796–802 (2008).
   PubMedGoogle Scholar
• Liu YC, Liu HY, Yang HW et al. Impaired expression and function of breast cancer resistance protein (Bcrp) in brain cortex of streptozocin-induced diabetic rats. Biochem. Pharmacol.74(12), 1766–1772 (2007).
   PubMed Web of Science ®Google Scholar
• Yang ZH, Liu XD. P-glycoprotein-mediated efflux of phenobarbital at the blood-brain barrier evidence from transport experiments in vitro. Epilepsy Res.78(1), 40–49 (2008).
   PubMed Web of Science ®Google Scholar
• Liu H, Zhang D, Xu X et al. Attenuated function and expression of P-glycoprotein at blood-brain barrier and increased brain distribution of phenobarbital in streptozotocin-induced diabetic mice. Eur. J. Pharmacol.561(1–3), 226–232 (2007).
   PubMed Web of Science ®Google Scholar
• Reichel V, Burghard S, John I, Huber O. P-glycoprotein and breast cancer resistance protein expression and function at the blood–brain barrier and blood–cerebrospinal fluid barrier (choroid plexus) in streptozotocin-induced diabetes in rats. Brain Res.1370, 238–245 (2011).
   PubMed Web of Science ®Google Scholar
• Maeng HJ, Kim MH, Jin HE et al. Functional induction of P-glycoprotein in the blood–brain barrier of streptozotocin-induced diabetic rats: evidence for the involvement of nuclear factor-κβ, a nitrosative stress-sensitive transcription factor, in the regulation. Drug Metab. Dispos.35(11), 1996–2005 (2007).
   PubMed Web of Science ®Google Scholar
• Hawkins BT, Ocheltree SM, Norwood KM, Egleton RD. Decreased blood–brain barrier permeability to fluorescein in streptozotocin-treated rats. Neurosci. Lett.411(1), 1–5 (2007).
   PubMedGoogle Scholar
• Wu KC, Pan HJ, Yin HS, Chen MR, Lu SC, Lin CJ. Change in P-glycoprotein and caveolin protein expression in brain striatum capillaries in New Zealand obese mice with Type 2 diabetes. Life Sci.85(23–26), 775–781 (2009).
   PubMed Web of Science ®Google Scholar
• Liu H, Xu X, Yang Z, Deng Y, Liu X, Xie L. Impaired function and expression of P-glycoprotein in blood-brain barrier of streptozotocin-induced diabetic rats. Brain Res.1123(1), 245–252 (2006).
   PubMed Web of Science ®Google Scholar
• Liu H, Liu X, Jia L et al. Insulin therapy restores impaired function and expression of P-glycoprotein in blood–brain barrier of experimental diabetes. Biochem. Pharmacol.75(8), 1649–1658 (2008).
   PubMed Web of Science ®Google Scholar
• Anger GJ, Piquette-Miller M. Impact of hyperlipidemia on plasma protein binding and hepatic drug transporter and metabolic enzyme regulation in a rat model of gestational diabetes. J. Pharmacol. Exp. Ther.334(1), 21–32 (2010).
   PubMed Web of Science ®Google Scholar
• Kameyama N, Arisawa S, Ueyama J et al. Increase in P-glycoprotein accompanied by activation of protein kinase Cα and NF-κB p65 in the livers of rats with streptozotocin-induced diabetes. Biochim. Biophys. Acta1782(5), 355–360 (2008).
   PubMed Web of Science ®Google Scholar
• Nawa A, Fujita Hamabe W, Tokuyama S. Inducible nitric oxide synthase-mediated decrease of intestinal P-glycoprotein expression under streptozotocin-induced diabetic conditions. Life Sci.86(11–12), 402–409 (2010).
   PubMed Web of Science ®Google Scholar
• Ghosh S, Ting S, Lau H et al. Increased efflux of glutathione conjugate in acutely diabetic cardiomyocytes. Can. J. Physiol. Pharmacol.82(10), 879–887 (2004).
   PubMed Web of Science ®Google Scholar
• Quezada C, Alarcon S, Carcamo JG et al. Increased expression of the multidrug resistance-associated protein 1 (MRP1) in kidney glomeruli of streptozotocin-induced diabetic rats. Biol. Chem.392(6), 529–537 (2011).
   PubMed Web of Science ®Google Scholar
• Anger G, Piquette-Miller M. Mechanisms of reduced maternal and fetal lopinavir exposure in a rat model of gestational diabetes. Drug Metab. Dispos.39(10), 1850–1859 (2011).
   PubMedGoogle Scholar
• Handschin C, Meyer UA. Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Arch. Biochem. Biophys.433(2), 387–396 (2005).
   PubMed Web of Science ®Google Scholar
• Nowicki MT, Aleksunes LM, Sawant SP, Dnyanmote AV, Mehendale HM, Manautou JE. Renal and hepatic transporter expression in Type 2 diabetic rats. Drug Metab. Lett.2(1), 11–17 (2008).
   PubMedGoogle Scholar
• More VR, Slitt AL. Alteration of hepatic but not renal transporter expression in diet-induced obese mice. Drug Metab. Dispos.39(6), 992–999 (2011).
   PubMed Web of Science ®Google Scholar
• Sugioka N, Haraya K, Fukushima K, Ito Y, Takada K. Effects of obesity induced by high-fat diet on the pharmacokinetics of nelfinavir, a HIV protease inhibitor, in laboratory rats. Biopharm. Drug Dispos.30(9), 532–541 (2009).
   PubMed Web of Science ®Google Scholar
• Ghose R, Omoluabi O, Gandhi A et al. Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters. Life Sci.89(1–2), 57–64 (2011).
   PubMed Web of Science ®Google Scholar
• Cheng Q, Aleksunes LM, Manautou JE et al. Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity. Mol. Pharm.5(1), 77–91 (2008).
   PubMed Web of Science ®Google Scholar
• Aleixandre De Artinano A, Miguel Castro M. Experimental rat models to study the metabolic syndrome. Br. J. Nutr.102(9), 1246–1253 (2009).
   PubMedGoogle Scholar
• Pizarro M, Balasubramaniyan N, Solis N et al. Bile secretory function in the obese Zucker rat: evidence of cholestasis and altered canalicular transport function. Gut53(12), 1837–1843 (2004).
   PubMed Web of Science ®Google Scholar
• Geier A, Dietrich CG, Grote T et al. Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat. J. Hepatol.43(6), 1021–1030 (2005).
   PubMed Web of Science ®Google Scholar
• Tirona RG. Molecular mechanisms of drug transporter regulation. Handb. Exp. Pharmacol.201, 373–402 (2011).
   PubMedGoogle Scholar
• Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol. Rev.83(2), 633–671 (2003).
   PubMed Web of Science ®Google Scholar
• Kosters A, Karpen S. The role of inflammation in cholestasis: clinical and basic aspects. Semin. Liver Dis.30(2), 186–194 (2010).
   PubMed Web of Science ®Google Scholar
• Yang H, Plosch T, Lisman T et al. Inflammation mediated down-regulation of hepatobiliary transporters contributes to intrahepatic cholestasis and liver damage in murine biliary atresia. Pediatr. Res.66(4), 380–385 (2009).
   PubMedGoogle Scholar
• Zollner G, Marschall HU, Wagner M, Trauner M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol. Pharm.3(3), 231–251 (2006).
   PubMed Web of Science ®Google Scholar
• Zollner G, Fickert P, Silbert D et al. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J. Hepatol.38(6), 717–727 (2003).
   PubMed Web of Science ®Google Scholar
• Wagner M, Zollner G, Trauner M. Nuclear receptor regulation of the adaptive response of bile acid transporters in cholestasis. Semin. Liver Dis.30(2), 160–177 (2010).
   PubMedGoogle Scholar
• Robertson GR, Liddle C, Clarke SJ. Inflammation and altered drug clearance in cancer: transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice. Clin. Pharmacol. Ther.83(6), 894–897 (2008).
   PubMed Web of Science ®Google Scholar
• Kacevska M, Robertson GR, Clarke SJ, Liddle C. Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Exp. Opin. Drug Metab. Toxicol.4(2), 137–149 (2008).
   PubMed Web of Science ®Google Scholar
• Henningsson A, Marsh S, Loos WJ et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin. Cancer Res.11(22), 8097–8104 (2005).
   PubMed Web of Science ®Google Scholar
• Porta C, Larghi P, Rimoldi M et al. Cellular and molecular pathways linking inflammation and cancer. Immunobiology214(9–10), 761–777 (2009).
   PubMed Web of Science ®Google Scholar
• Moore MM, Chua W, Charles KA, Clarke SJ. Inflammation and cancer: causes and consequences. Clin. Pharmacol. Ther.87(4), 504–508 (2010).
   PubMed Web of Science ®Google Scholar
• Aitken AE, Richardson TA, Morgan ET. Regulation of drug-metabolizing enzymes and transporters in inflammation. Ann. Rev. Pharmacol. Toxicol.46, 123–149 (2006).
   PubMed Web of Science ®Google Scholar
• Sharma R, Kacevska M, London R, Clarke SJ, Liddle C, Robertson G. Downregulation of drug transport and metabolism in mice bearing extra-hepatic malignancies. Br. J. Cancer98(1), 91–97 (2008).
   PubMedGoogle Scholar
• Charles KA, Rivory LP, Brown SL, Liddle C, Clarke SJ, Robertson GR. Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clin. Cancer Res.12(24), 7492–7497 (2006).
   PubMed Web of Science ®Google Scholar
• Kacevska M, Downes MR, Sharma R et al. Extrahepatic cancer suppresses nuclear receptor-regulated drug metabolism. Clin. Cancer Res.17(10), 3170–3180 (2011).
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Cancer and inflammation: implications for pharmacology and therapeutics. Clin. Pharmacol. Ther.87(4), 401–406 (2010).
   PubMed Web of Science ®Google Scholar
• Ho EA, Piquette-Miller M. KLF6 and HSF4 transcriptionally regulate multidrug resistance transporters during inflammation. Biochem. Biophys. Res. Commun.353(3), 679–685 (2007).
   PubMedGoogle Scholar
• Teng S, Piquette-Miller M. Regulation of transporters by nuclear hormone receptors: implications during inflammation. Mol. Pharm.5(1), 67–76 (2008).
   PubMed Web of Science ®Google Scholar
• Yu C, Argyropoulos G, Zhang Y, Kastin AJ, Hsuchou H, Pan W. Neuroinflammation activates Mdr1b efflux transport through NFκB: promoter analysis in BBB endothelia. Cell. Physiol. Biochem.22(5–6), 745–756 (2008).
   PubMedGoogle Scholar
• Pan W, Yu C, Hsuchou H, Kastin AJ. The role of cerebral vascular NFκB in LPS-induced inflammation: differential regulation of efflux transporter and transporting cytokine receptors. Cell. Physiol. Biochem.25(6), 623–630 (2010).
   PubMedGoogle Scholar
• Mulder J, Karpen SJ, Tietge UJ, Kuipers F. Nuclear receptors: mediators and modifiers of inflammation-induced cholestasis. Front. Biosci.14, 2599–2630 (2009).
   Google Scholar
• Ghose R, Zimmerman TL, Thevananther S, Karpen SJ. Endotoxin leads to rapid subcellular re-localization of hepatic RXRα: a novel mechanism for reduced hepatic gene expression in inflammation. Nucl. Recept.2(1), 4 (2004).
   PubMedGoogle Scholar
• Kosters A, White DD, Sun H, Thevananther S, Karpen SJ. Redundant roles for cJun-N-terminal kinase 1 and 2 in interleukin-1β-mediated reduction and modification of murine hepatic nuclear retinoid X receptor α. J. Hepatol.51(5), 898–908 (2009).
   PubMed Web of Science ®Google Scholar
• Zimmerman TL, Thevananther S, Ghose R, Burns AR, Karpen SJ. Nuclear export of retinoid X receptor α in response to interleukin-1β-mediated cell signaling: roles for JNK and SER260. J. Biol. Chem.281(22), 15434–15440 (2006).
   PubMed Web of Science ®Google Scholar
• Kosters A, Karpen SJ. The role of inflammation in cholestasis: clinical and basic aspects. Semin. Liver Dis.30(2), 186–194 (2010).
   PubMed Web of Science ®Google Scholar
• Teng S, Piquette-Miller M. The involvement of the pregnane X receptor in hepatic gene regulation during inflammation in mice. J. Pharmacol. Exp. Ther.312(2), 841–848 (2005).
   PubMed Web of Science ®Google Scholar
• Zinchuk V, Zinchuk O, Okada T. Experimental LPS-induced cholestasis alters subcellular distribution and affects colocalization of Mrp2 and Bsep proteins: a quantitative colocalization study. Microsc. Res. Tech.67(2), 65–70 (2005).
   PubMedGoogle Scholar
• Saeki J, Sekine S, Horie T. LPS-induced dissociation of multidrug resistance-associated protein 2 (Mrp2) and radixin is associated with Mrp2 selective internalization in rats. Biochem. Pharmacol.81(1), 178–184 (2011).
   PubMedGoogle Scholar
• Mottino AD, Cao J, Veggi LM, Crocenzi F, Roma MG, Vore M. Altered localization and activity of canalicular Mrp2 in estradiol-17beta-D-glucuronide-induced cholestasis. Hepatology35(6), 1409–1419 (2002).
   PubMed Web of Science ®Google Scholar
• Crocenzi FA, Mottino AD, Cao J et al. Estradiol-17beta-D-glucuronide induces endocytic internalization of Bsep in rats. Am. J. Physiol. Gastrointest. Liver Physiol.285(2), G449–G459 (2003).
   PubMed Web of Science ®Google Scholar